Copyright © 2021. Inderes Oyj. All rights reserved.

Novartis has reported negative headline data from its Phase III CANOPY-2 trial, investigating canakinumab (anti-IL1beta) with docetaxel for 2nd/3rd-line NSCLC. Cantargia’s lead asset CAN04 (anti-IL1RAP) is a potential competitor. While we acknowledge that Novartis’s data has created negative sentiment, we believe CAN04 is clearly differentiated. Cantargia’s Phase IIa CANFOUR trial investigates CAN04 in a combination with a different chemotherapy (platinum-based as opposed to docetaxel in the Novartis trial) and CAN04 blocks the signalling from both IL-1alpha and IL-1beta (recent interim data from the CANFOUR trial was positive). In addition, CAN04 has been show to effectively induce cancer cell death by an established mechanism ADCC (antibody-dependent cellular cytotoxicity). Ultimately, Novartis’s results will add to the totality of data and help Cantargia define CAN04’s positioning. Near-term catalysts are the readout from Novartis’s Phase III CANOPY-1 trial (H221, front line setting) and updated results from Cantargia’s Phase IIa CANFOUR trial (2021).

Lähde: Finwire News

Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer.